SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Psilocybin and Motor Function: A Triple‐Blind, Dose‐Finding Study in Healthy Participants

Bhagavan, C; Kanaan, R; Carter, O; Nielsen, G; Berlowitz, D; Issak, S; Braat, S; Zaloumis, S; Attard, Z; Oliver, G; et al. Bhagavan, C; Kanaan, R; Carter, O; Nielsen, G; Berlowitz, D; Issak, S; Braat, S; Zaloumis, S; Attard, Z; Oliver, G; Mayne, D; McKernon, D; Roebuck, G; Rucker, J; Butler, M; Bryson, A (2024) Psilocybin and Motor Function: A Triple‐Blind, Dose‐Finding Study in Healthy Participants. Psychiatric Research and Clinical Practice, 6 (4). pp. 164-174. ISSN 2575-5609 https://doi.org/10.1176/appi.prcp.20240047
SGUL Authors: Nielsen, Glenn

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (472kB) | Preview

Abstract

Background: There has been a resurgence of research into the potential therapeutic benefits of psychedelics for neuropsychiatric disorders. Classic psychedelics, such as psilocybin, exert complex effects on higher cognitive functions such as perception and awareness, but their impact on motor function remains unexplored. Moreover, there is a theoretical rationale for using psychedelics to promote motor retraining in certain neuropsychiatric conditions associated with motor dysfunction. This protocol paper outlines the first study to investigate the feasibility and safety of performing movement tasks during the acute effects of psilocybin in healthy participants. The findings from this study will further our understanding of the impact of psychedelics on motor function, and inform future studies that combine classic psychedelics with motor retraining in clinical populations. Methods: 12 healthy participants will each receive three doses of psilocybin (between 5 and 20 mg) in a randomized order, with each dose administered at least 1 week apart. Participants, the trial physiotherapists, and statisticians will remain blinded to the psilocybin dose. A battery of measures assessing motor function will be completed during the acute drug effects. In addition, measures of safety, pre‐ and post‐dose resting‐state brain activity via functional magnetic resonance imaging, and participants' subjective experience will be assessed.

Item Type: Article
Additional Information: This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. © 2024 The Author(s). Psychiatric Research and Clinical practice published by Wiley Periodicals LLC on behalf of American Psychiatric Association.
Journal or Publication Title: Psychiatric Research and Clinical Practice
ISSN: 2575-5609
Language: en
Dates:
DateEvent
11 December 2024Published
23 July 2024Published Online
23 June 2024Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
URI: https://openaccess.sgul.ac.uk/id/eprint/116710
Publisher's version: https://doi.org/10.1176/appi.prcp.20240047

Actions (login required)

Edit Item Edit Item